The case for & against
Bull & Bear analysis
Bearish
MediWound Ltd. (NASDAQ: MDWD) operates in the biopharmaceutical sector, focusing on innovative therapies for chronic wounds and severe burns, particularly through its enzymatic debridement products, Escarex and NexoBrid. The company is strategically positioned within a growing sector, harnessing government contracts and collaborations to expand its market presence as it navigates challenges pertaining to clinical trials, regulatory hurdles, and geopolitical tensions impacting operations.
Bull says
- ↑2026 revenue guidance at $24–26M, targeting strong YoY recovery
- ↑NexoBridge facility expands capacity six-fold, operational by end-2025
- ↑10-year BARDA contract up to $197M underpins government procurement
- ↑Medicare reimbursement changes favor clinically proven Escarex adoption
- ↑Strong growth factor and positive earnings revisions support upside
- ↑Cash balance $45M funds operations; CEO forecasts $32–35M in 2027
Bear says
- ↓Q1 2026 revenue fell to $1.5M from $4M in Q1 2025
- ↓Net loss of $3M and $7M EBITDA deficit intensify cash burn
- ↓Heavy reliance on BARDA funding poses revenue volatility risks
- ↓Absence of CPT code may delay market adoption of products
- ↓Negative earnings yield and high volatility signal valuation pressure
- ↓Low liquidity and small size factor raise execution uncertainty
Investment themes with MDWD
Pharmaceuticals↓ -0.08%
Drug development driving global healthcare solutions
LLY · JNJ · MRK
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 05-27-2026neutral
Transcript signals
Bull points
- We entered 2025 with strong execution across our clinical, commercial, and operational priorities, maintaining the momentum we established in 2024.
- Nexobrit continues to gain global traction as we advance long-term manufacturing investments to support sustained growth.
- Recruitment for the value phase III study for venous leg ulcers is progressing as planned, with the global trial to enroll 216 patients across approximately 40 sites in the United States and Europe.
Bear points
- Total revenue for the first quarter of 2025 was $4 million, compared to $5 million in the first quarter of 2024. The decline reflects lower revenue from BARDA-funded development services, as the NexoBRI development program for both adult and pediatric population approaches completion.
- Operating loss for the quarter was $5.2 million versus $3.7 million in June 2024.
- Adjusted EBITDA loss for the quarter was $4 million compared to $2.9 million in the prior year period.
Read full transcript analysis ›